Tiziana Life Sciences PLC B. Riley Virtual Neuroscience Investor Conference

TIDMTILS

Tiziana Life Sciences PLC

27 April 2021

Tiziana Life Sciences to participate in a Fireside Chat

on 28 April 2021 at 10:30 a.m. EDT

NEW YORK and LONDON - 27 April 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai and the chair of its Scientific Advisory Committee, Dr Howard Weiner, will participate in a fireside chat via a video link on Wednesday, 28 April 2021 at 10:30 a.m. EDT (US and Canada) to provide updates on the Company. Please note that only information which is already in the public domain will be discussed.

 
Date:     Wednesday, 28 April 2021 
Time:     10:30 a.m. - 11:00 a.m. Eastern Daylight Savings Time (US and Canada) 
Webcast:  https://www.webcaster4.com/Webcast/Page/2433/41045

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom Investors:

 
Tiziana Life Sciences plc 
 Gabriele Cerrone, Chairman and founder   +44 (0)20 7495 2379

United States Investors:

 
Dave Gentry              Office 1 800 RED CHIP (733 
 RedChip Companies Inc.   2447) 
                          Cell 407-491-4498 (USA) 
                          dave@redchip.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAELKASAFEAA

(END) Dow Jones Newswires

April 27, 2021 02:00 ET (06:00 GMT)

Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jun 2024 to Jul 2024